Rezolute to Participate in the BTIG Virtual Biotechnology Conference
2024年7月31日 - 9:00PM
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a
late-stage biopharmaceutical company committed to developing
novel, transformative therapies for serious rare diseases, today
announced that Nevan Charles Elam, Chief Executive Officer and
Founder of Rezolute, will participate in a fireside chat during the
BTIG Virtual Biotechnology Conference on Monday, August 5, 2024, at
12:00 p.m. ET.
Management will be participating in one-on-one
investor meetings throughout the conference. Investors interested
in scheduling a meeting with the Rezolute management team should
contact their BTIG representative.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company
focused on significantly improving outcomes for individuals with
hypoglycemia caused by hyperinsulinism (HI). The Company’s
antibody therapy, RZ358, is designed to treat all forms of HI and
has shown substantial benefit in clinical trials and real-world use
for the treatment of congenital hyperinsulinism (cHI) and tumor
hyperinsulinism (tHI).
Contacts:
Rezolute, Inc.Christen
Baglaneascbaglaneas@rezolutebio.com508-272-6717
LHA Investor RelationsTirth T.
Pateltpatel@lhai.com212-201-6614
Rezolute (NASDAQ:RZLT)
過去 株価チャート
から 7 2024 まで 8 2024
Rezolute (NASDAQ:RZLT)
過去 株価チャート
から 8 2023 まで 8 2024